Company Profile
Intellia Stock Price, News & Catalysts
- Ticker:
- NTLA
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
12.09 USD (+0.58%)
Close
Last updated: August 12, 2026
1.83B USD
Market cap
Why the stock is moving
As of Aug 12, 2026, NTLA closed up 0.58% at $12.09. No new same-company headline was identified in the current news window.
Company overview
In Vivo CRISPR Gene Editing
Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies.
Hereditary Angioedema
Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed to reduce kallikrein production for hereditary angioedema. Positive Phase 3 HAELO results support a rolling BLA submission.
Transthyretin Amyloidosis
Nexiguran ziclumeran, or nex-z, targets the TTR gene to reduce production of transthyretin through a one-time in vivo edit.
ATTR Cardiomyopathy Program
The Phase 3 MAGNITUDE trial evaluates nex-z in transthyretin amyloidosis with cardiomyopathy, the larger of Intellia's two registrational ATTR indications.
Hereditary ATTR Polyneuropathy
MAGNITUDE-2 evaluates nex-z in hereditary transthyretin amyloidosis with polyneuropathy, extending the same editing candidate into a neurologic manifestation of the disease.
Future catalysts
- Completion of the rolling BLA submission for lonvo-z.
- Potential U.S. launch of lonvo-z in the first half of 2027, subject to approval.
Recent news
- 01
- 02
- 03
- 04
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Intellia (NTLA)?
Intellia (NTLA) most recently closed at 12.09 USD, a +0.58% move versus the previous session.
What is the market cap of Intellia (NTLA)?
Intellia currently has a market capitalization of 1.83B USD on BioPharmSignal.
What does Intellia do?
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed to reduce kallikrein...
On which exchange is NTLA stock listed?
Intellia (NTLA) is associated with NASDAQ, United States, Biopharma.
What is MAGNITUDE-2?
Hereditary ATTR Polyneuropathy MAGNITUDE-2 evaluates nex-z in hereditary transthyretin amyloidosis with polyneuropathy, extending the same editing candidate into a neurologic manifestation of the disease.
Which conditions is Intellia targeting with MAGNITUDE-2?
In Vivo CRISPR Gene Editing Intellia Therapeutics develops potentially one-time medicines using CRISPR-based gene editing. Its lead programs edit disease-causing genes directly inside the body through systemically delivered therapies. Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed to reduce kallikrein...
How does Intellia describe recent progress with MAGNITUDE-2?
Completion of the rolling BLA submission for lonvo-z. Potential U.S. launch of lonvo-z in the first half of 2027, subject to approval.
What is ziclumeran?
Hereditary Angioedema Lonvoguran ziclumeran, or lonvo-z, is an in vivo gene-editing candidate designed to reduce kallikrein production for hereditary angioedema.